www .lakemedelsakademin.se

www.lakemedelsakademin.se
3rd
Anglo-Swedish Medicinal
Chemistry Symposium
March 11th-14th, 2007
Åre, Sweden

Introduction
This conference is the 3rd meeting organized jointly between
the Medicinal Chemistry Section of the Swedish Academy of
Pharmaceutical Sciences and the Royal Society of Chemistry,
Biological and Medicinal Chemistry Sector to promote the very
best of medicinal chemistry in a stimulating environment. The
1st and 2nd Symposia were successfully held in 2003 and 2005
respectively, each with over 100 delegates from all over the
world.
Programme Outline
The Programme consists of six sessions. Many of the medicinal
chemistry talks will be first disclosures whilst the ‘enabling
sessions’ on lead generation and drug metabolism will be presented
by experts from across the industry and academia. This
symposium is also designed to provide plenty of opportunities
to meet other delegates, renew friendships and foster new contacts.
Poster Session
Participants are encouraged to present a poster in English.
Please indicate on the booking form if you intend to do a poster
presentation. Poster abstracts should be sent electronically to
Göran Lidgren, goran.lidgren@swepharm.se, by 31st January
2007. Abstract instructions will be mailed out with the booking
confirmation.
Organizing Committee
David Alker, David Alker Associates, UK
Thomas Elebring, AstraZeneca, Sweden
Carlos Garcia-Echeverria, Novartis Institutes for Biomedical Research,
Switzerland
Adrian Hall, GlaxoSmithKline, UK
Charles Hedgecock, Biovitrum, Sweden
Alexander Humphries, AstraZeneca, UK
Märit Johansson, Swedish Academy of Pharmaceutical Sciences, Sweden
Göran Lidgren, Swedish Academy of Pharmaceutical Sciences, Sweden
Austen Pimm, AstraZeneca, UK
Sunday Evening Registration, Dinner and Social Mixer
Monday Morning Session Kinases and ATPases
Evening session
Drug Delivery and Metabolism; the
Issues Facing a Medicinal Chemist
Tuesday Morning session Enzyme Inhibitors
Evening session
Lead Generation
Wednesday Morning session GPCRs and Nuclear Receptors
Evening session
Ion Channels
Location, Venue, Language
The meeting takes place at Hotel Åre Fjällby, which is situated
in Åre, a popular Ski Resort in Sweden, located about 600
km North from Stockholm. Registration opens at 18.00 hrs on
March 11th and the scientific programme starts at 08.30 hrs
March 12th and ends with a conference dinner at 19.00 hrs
Wednesday March 14th. The meeting will be held in English.
Participation fee and Accommodation
The registration fee is SEK 6600* for industry delegates and
SEK 5500* for academic researchers if registration is received
before 8th January, 2007. From that date the fees are
SEK 8100* for industry and SEK 7000* for academic.
The price for full room and board, Sunday-Thursday (4 nights),
is 5900 SEK* and will be added on the invoice.
* (excl. VAT)
Early registration is strongly recommended due to limited
number of seats!
Cancellations, Substitutions
The registration fee and costs for accommodation will be
reimbursed in full if written cancellation is received before 8th
January, 2007. Cancellations received after this date are not
reimbursable. A substitute participant is of course welcome to
attend, but please always inform the responsible Symposium
Secretary.
Further Information
If you have any questions about this meeting please contact
Symposium Secretary Diana Mickels. phone +46 (0) 8-7235085,
diana.mickels@lakemedelsakademin.se
Registration can be made on www.lakemedelsakademin.se

PROGRAMME
Sunday 11th March
18:00 Registration
19:00 Dinner
20:00 Social Mixer
Monday 12th March
Morning Session: Kinases and ATPases
Chairman: Carlos Garcia-Echeverria, Novartis Institutes for Biomedical
Research, Switzerland
Session programme:
08:30 Identification of a CDK1/2 drug candidate using fragment based
discovery
Miles Congreve, Astex Therapeutics, UK
09:15 Structure based discovery of Hsp90 inhibitors for the treatment of
cancer
Martin Drysdale, Vernalis, UK
10:00 Coffee
10:30 The discovery of novel IKK inhibitors
John Christopher, GlaxoSmithKline, UK
11:15 Inhibitors of Oncogenic B-Raf: Discovery and Path to the Clinic
Rick Artis, Plexxikon Inc., Berkeley, USA
12:00-17:00 Free
Evening Session: Drug Delivery and Metabolism – the Issues Facing a
Medicinal Chemist
Chairman: Thomas Elebring, AstraZeneca R&D Mölndal, Sweden
Session programme:
17:00 Covalent binding and reactive metabolites
Tom Baillie, Merck Research Laboratories, West Point, USA
17.40 Screening for physicochemical properties in drug discovery
Anders G. Holmen, AstraZeneca R&D Mölndal, Sweden
18:20 “CNS drug delivery”
Alex Stevens, GlaxoSmithKline, UK
19:15 Dinner
20:15 Social Mixer
Tuesday 13th March
Morning Session: Enzyme Inhibitors
Chairman: Charles Hedgecock, Biovitrum AB, Stockholm, Sweden
Session programme:
08:30 Chemistry, Biology and Development of a Cyanopyrrolidine
Type DPP-IV Inhibitor
Daniel Hunziker, F. Hoffmann-La Roche Ltd, Switzerland
09:15 The discovery of MK-0822 - a cathepsin K inhibitor for the
treatment of osteoporosis
Cameron Black, Merck Frosst Centre for Therapeutic Research,
Canada
10:00 Coffee
10:30 Discovery and Optimisation of Acylureas as Glycogen
Phosphorylase Inhibitors
Elisabeth Defossa, Sanofi-Aventis Deutschland GmbH, Germany
11:15 Novel Macrocyclic inhibitors of the HCV NS3 protease-Discovery
and preclinical characterization
Åsa Rosenquist, Medivir AB, Sweden
12:00-17:00 Free
Evening Session: Lead Generation
Chairman: Austen Pimm, AstraZeneca, Charnwood, UK
Session programme:
17:00 2,5-Diketopiperazines as potent and selective oxytocin
antagonists: from lead identification to clinical candidate
Deirdre Hickey, GlaxoSmithKline, UK
17:40 The CV/GI Active-to-Hit Process
Kay Brickmann, AstraZeneca R&D Mölndal, Sweden
18:20 Parallel M3 receptor potency and binding kinetics studies for the
selection of leads leading to development candidates
Steve Collingwood, Novartis Institutes for Biomedical Research,
UK
19:15 Dinner
20:00-22:00 Poster Session
Wednesday 14th March
Morning Session: GPCRs and Nuclear Receptors
Chairman: Adrian Hall, GlaxoSmithKline, UK
Session Programme:
08:30 Azadecalin as a Scaffold for Selective Glucocorticoid Receptor
Antagonists
Nick Ray, Argenta Discovery Ltd, UK
09:15 Discovery and evaluation of A1 agonists for the potential
treatment of pain
Neil Miller, Neurology & GI CEDD, GlaxoSmithKline, Singapore
10:00 Coffee
10:30 The Discovery and Development of Selective 5-HT2C Receptor
Agonists
Andrew Williams, Eli Lilly and Company Ltd, UK
11:15 Allosteric modulation of GPCRs
Udo Bauer, AstraZeneca R&D Mölndal, Sweden
12:00-17:00 Free
Evening Session: Ion Channels
Chairman: Alex Humphries, AstraZeneca R& D, Charnwood, UK
Session programme
17:00 NR2B Subtype Selective NMDA Receptor Antagonists
John McCauley, Merck Research Laboratories, USA
17:40 Positive and Negative Modulation of Small Conductance
Ca2+ activated K+ channels
Birgitte Eriksen, NeuroSearch A/S, Denmark
18:20 Novel a2δ ligands for the treatment of neuropathic pain
David Rawson, Pfizer Global R&D, Sandwich Labs, UK
19:30-21:00 Conference Dinner
For continuously updated programme see www.lakemedelsakademin.se

B
SVERIGE
PORTO BETALT
PORT PAYÉ
Media sponsor:
Registration can also be made on our home page www.lakemedelsakademin.se
Booking Form
3rd Anglo-Swedish Medicinal Chemistry Symposium, March 11th–14th, 2007
Please register me for the 3rd Anglo Swedish Medicinal Chemistry Symposium
• I am an industry delegate • I am an academic researcher
• I wish to present a poster.
Poster Title:
Name:
Company incl. building:
Date of Birth (yymmdd):
Department:
Company Address:
Post Code:
City:
Invoice Address if not the above:
Phone: Mobile: Fax:
E-mail:
Please indicate any special requirements (e.g. Dietary):
Date
Signature
Fax: +46-(0)8-20 55 11
Mail: Läkemedelsakademin, att: Diana Mickels, P.O. Box 1136, SE-111 81 Stockholm, Sweden. 10210/DmsGln
Layout & Production: Lådan & Co. Photo: Bosse Lind/paragonbild.se (cover) and Skistar AB. 2006.
www.lakemedelsakademin.se